Evaluation of Tolerability, Pharmacokinetics and Pharmacodynamics of Vicagrel, a Novel P2Y12 Antagonist, in Healthy Chinese Volunteers-Reference-Cited by-同舟云学术

Evaluation of Tolerability, Pharmacokinetics and Pharmacodynamics of Vicagrel, a Novel P2Y12 Antagonist, in Healthy Chinese Volunteers

Published:2018-06-20 Issue: Volume:9 Page:
ISSN:1663-9812
Container-title:Frontiers in Pharmacology
language:
Short-container-title:Front. Pharmacol.

Author:

Li Xiaojiao,Liu Cai,Zhu Xiaoxue,Wei Haijing,Zhang Hong,Chen Hong,Chen Guiling,Yang Deming,Sun Hongbin,Shen Zhenwei,Zhang Yifan,Li Wei,Yang Jin,Liu Yongqiang,Lai Xiaojuan,Gong Yanchun,Liu Xuefang,Li Yongguo,Zhong Dafang,Niu Junqi,Liu Bin,Ding Yanhua

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference34 articles.

1. Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist;Anderson;Ann. Pharmacother.,2010

2. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomized controlled superiority trial;Cayla;Lancet,2016

3. Pharmacokinetics and pharmacodynamics of single and multiple doses of prasugrel in healthy native Chinese subjects;Cui;Acta. Pharmacol. Sin.,2012

4. Physiologically based pharmacokinetic modeling for sequential metabolism: effect of CYP2C19 genetic polymorphism on clopidogrel and clopidogrel active metabolite pharmacokinetics;Djebli;Drug. Metab. Dispos.,2015

5. Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety;Dobesh;Pharmacotherapy,2014

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decreased plasma exposure of clopidogrel active metabolite in rats after long‐term treatment with clopidogrel;Biopharmaceutics & Drug Disposition;2023-03-11

2. Vicagrel is hydrolyzed by Raf kinase inhibitor protein in human intestine;Biopharmaceutics & Drug Disposition;2022-12

3. Influence of Genetic and Epigenetic Factors of P2Y12 Receptor on the Safety and Efficacy of Antiplatelet Drugs;Cardiovascular Drugs and Therapy;2022-08-09

4. Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug–Drug–Gene Interaction Predictions;Pharmaceutics;2022-04-22

5. Antiplatelet effect, safety, and pharmacokinetics of vicagrel in patients with coronary artery disease undergoing percutaneous coronary intervention;European Heart Journal - Cardiovascular Pharmacotherapy;2022-04-19